Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients’ survival: PEACH study

Tanaka, Yusuke; Ueda, Yutaka; Egawa-Takata, Tomomi; Matsuzaki, Shinya; Kobayashi, Eiji; Yoshino, Kiyoshi; Enomoto, Takayuki; Tatsumi, Mitsuaki; Kimura, Tadashi

doi:10.1007/s00280-015-2935-0

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ideally, it might be necessary to evaluate the five target lesions evaluated in RECIST 1.1. However, as RECIST 1.1 suggests that just three lesions (not five lesions) may be used in randomized studies in which tumor progression is the major concern [10,11], the number of lesions to evaluate when assessing response to therapy may also be important in both RECIST and PERCIST. Further study from this viewpoint will be needed in the future.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors

Han

Song

Guo³

et al. 2022

Nuclear Medicine Communications

View full text Add to dashboard Cite

Objective Recommendations for surveillance after stereotactic body radiation therapy (SBRT) for early-stage nonsmall cell lung cancer (NSCLC) are not well defined. Recently, PET response criteria in solid tumors (PERCIST) have been proposed as a new standardized method to assess radiotherapeutic response both quantitatively and metabolically. The aim of this study was to evaluate therapeutic response following SBRT in early-stage NSCLC patients by comparing PERCIST with the currently widely used RECIST. Materials and methodsForty-nine patients with early-stage NSCLC who had been prescribed SBRT were studied. Responses of lesion were evaluated using CT and 18 F-FDG PET according to the RECIST and PERCIST methods. PET-CT scans were obtained before SBRT and 3-6 months after SBRT. Associations between overall survival (OS) and clinicopathologic results (histology, tumor location, tumor size, lymphatic invasion, clinical stage, and radiotherapeutic responses in RECIST and PERCIST) were statistically analyzed. The median patient follow-up was 30 months. ResultsThirteen patients had stage IA, 9 stage IB, 10 stage IIA, and 17 stage IIB biopsy-proven NSCLC. Threeyear OS was 79.6%. CT scans indicated three regional recurrences. PET-CT/chest indicated three regional recurrences and distant metastasis. Significant differences were observed in response classification between RECIST and PERCIST (Wilcoxon signed-rank test, P = 0.0041). Univariate analysis showed that clinical stage, RECIST, and PERCIST were significant factors associated with OS, whereas by multivariate analysis PERCIST was the only predictor of OS. SMD, PMD/PMR, and CMR in PERCIST criteria were indicative of a 9.900-fold increase in the risk of OS in early NSCLC patients [risk ratio, 9.900 (95% CI, 1.040-21.591); P = 0.001]. ConclusionRECIST based on the anatomic size reduction rate did not demonstrate the correlation between radiotherapeutic response and prognosis in patients with early-stage NSCLC receiving SBRT. However, PERCIST was shown as the strongest independent predictor of outcomes. PERCIST might be considered more suitable for the evaluation of NSCLC tumor response to SBRT than

show abstract

Section: Discussionmentioning

confidence: 99%

“…PET-CT performed with the glucose analog 18F-fluorodeoxyglucose ( 18 F-FDG) has been established as an imaging modality for the evaluation of metabolic activity in oncology [10,11]. The technique has been reported to be more informative compared with CT alone for the evaluation of treatment response after chemotherapy [12].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors

Han

Song

Guo³

et al. 2022

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…PET-CT performed with the glucose analog 18 F-FDG has been established as an imaging modality for evaluation metabolic activity in oncology [10,11]. The technique has been reported to be more informative compared to CT alone for the evaluation of treatment response after chemotherapy [12].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Response to Stereotactic Body Radiation Therapy For Non-Small Cell Lung Cancer: PET Response Criteria in Solid Tumors (PERCIST) Versus Response Evaluation Criteria in Solid Tumors (RECIST)

Han¹,

Song²,

Guo³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Recommendations for surveillance after stereotactic body radiation therapy (SBRT) for early stage non–small cell lung cancer (NSCLC) are not well defined. Recently, PET response criteria in solid tumors (PERCIST) have been proposed as a new standardized method to assess radiotherapeutic response both quantitatively and metabolically. The aim of this study was to evaluate therapeutic response following Stereotactic Body Radiotherapy in early-stage Non-Small Cell Lung Cancer patients by comparing PERCIST with the currently widely used RECIST.Methods: Forty-nine patients with early-stage Non-Small Cell Lung Cancer who had been prescribed Stereotactic Body Radiotherapy were studied. Responses of lesion were evaluated using CT and 18F-FDG PET according to the RECIST and PERCIST methods. PET-CT scans were obtained before SBRT and 3 to 6 months after SBRT. Associations between overall survival and clinicopathologic results (histology, tumor location, tumor size, lymphatic invasion, clinical stage, radiotherapeutic responses in RECIST and PERCIST) were statistically analyzed. Median patient follow-up was 30 months.Results: Thirteen patients had stage IA, 9 stage IB, 10 stage IIA, and 17 stage IIB biopsy-proven NSCLC. Three-year overall survival was 79.6%. CT scans indicated 3 regional recurrences. PET/d-chest indicated 3 regional recurrences and distant metastasis. Significant differences were observed in response classification between RECIST and PERCIST (Wilcoxon signed-rank test, P=0.0041). Uni-variate analysis showed that clinical stage, RECIST and PERCIST were significant factors associated with overall survival, whilst by multivariate analysis PERCIST was the only predictor of overall survival. SMD, PMD/PMR, CMR in PERCIST criteria was indicative of a 9.900-fold increase in the risk of overall survival in early NSCLC patients [RR 9.900 (95% CI 1.040, 21.591), P=0.001].Conclusion: RECIST based on the anatomic size reduction rate did not demonstrate correlation between radiotherapeutic response and prognosis in patients with early-stage NSCLC receiving SBRT. However, PERCIST was shown as the strongest independent predictor of outcomes. PERCIST might be considered more suitable for evaluation of NSCLC tumour response to SBRT than RECIST.

show abstract

Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers

Zukotynski

Kim

2017

PET Clinics

View full text Add to dashboard Cite

Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients’ survival: PEACH study

Abstract: Early FDG-PET assessment by measuring the single largest lesion is a very promising tool for rapidly predicting tumor responses and patient survival, regardless of the chemotherapy regimen.

Cited by 3 publications

References 17 publications

Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors

Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors

Evaluation of Response to Stereotactic Body Radiation Therapy For Non-Small Cell Lung Cancer: PET Response Criteria in Solid Tumors (PERCIST) Versus Response Evaluation Criteria in Solid Tumors (RECIST)

Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers

Contact Info

Product

Resources

About